Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$5.27
▲ $0.08 (+1.5%)
Market data updated: 09/30 08:22 PM
Fundamentals updated: 09/30/2026
News analyzed: 09/30/2026
Market Cap
$288.64M
Day Range
$5.15 - $5.45
52-Week Range
$4.99 - $33.68
Beta
—
Next Earnings
03.11.2026
Support
$4.99
Resistance
$7.70
UPB is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-72.0% (1Y)
Strengths: 9/28 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Revenue growth (last year)
Revenue growth (last year): 20.4%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: -$46.23 vs. price $5.27 (-977.2%)
Fair Value
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 3 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 3
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
45
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
54
Quality
47
Value
38
Momentum
33
Risk
46
Sentiment
92
Fundamental
34
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Upstream Bio has centered on its progress in advancing verekitug, a potential treatment for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). The company announced plans for two pivotal Phase 3 trials, scheduled to begin in Q1 2027, following FDA discussions that shaped the trial design. Analysts have maintained mixed but generally positive outlooks, with some reiterating "Buy" ratings despite adjusted price targets. Additionally, Upstream Bio reported a Q2 loss while exceeding revenue estimates, signaling cautious optimism about its pipeline.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Upstream Bio, Inc.. News trend score: 92. Reason: 9 of the last 20 articles are positive, versus 2 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
21
🎯 Conviction (vs. Emotion)
37
Psychology
64
Fundamentals
34
Technical
33
Valuation
38
A significant decline over time, but on unusually low trading volume — holders unwilling to accept the loss.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Price (3M)
-30%
Market Narrative
50
Fundamental Reality
37
Narrative Gap
+13
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior suggests a narrative-reality gap (49 vs. 37) where positive sentiment (92/100) clashes with weak momentum and peer alignment. Herding dominates (49) as UPB’s modest underperformance (-1.2%) mirrors broader sector weakness (-1.9%), while loss aversion (16) hints at defensive holding despite recent declines. The key question: *Is the positive sentiment a lagging indicator, or will it drive a rebound despite technical weakness?* Anchoring (20) may cap upside near support, but panic selling (44) could emerge if volume spikes further.
Updated: 09/06/2026, 05:11 PM
What could change this?
👥 What the crowd believes
"Upstream Bio is on track to initiate Phase 3 clinical trials of verekitug in severe asthma and CRSwNP"
"JP Morgan analyst raises price target from $8 to $9"
"Upstream Bio delivered earnings and revenue surprises of +6.41% and +15.37%, respectively"
"Following productive FDA discussions, Upstream Bio will study 400 mg of verekitug"
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Benjamin Graham — 100/100
🔴 Weakest match
Thorstein Veblen — 12/100
🗣️ Why do they disagree?
The stark divide in verdicts for UPB reflects a clash between defensive, value-driven methodologies and more speculative or market-sensitive approaches. Benjamin Graham’s *Defensive Investor* and Walter Bagehot’s liquidity-focused framework both score perfectly, signaling a rock-solid balance sheet and resilience—ideal for cautious, risk-averse strategies. Meanwhile, Peter Lynch’s growth lens and Howard Marks’ market-cycle analysis also see upside, suggesting the stock’s price hasn’t yet reflected its fundamentals or broader economic positioning. However, the lower scores from Fisher, Livermore, and Veblen reveal deep skepticism: Fisher dismisses it for lacking his signature quality, Livermore flags a negative trend, and Veblen’s critique implies speculative overreach. The middle ground—where Marks (generalist), Schwager (disciplined trading), and even Nelson (cycle-based) still find merit—shows a consensus that UPB isn’t a slam dunk but could work for patient, rule-bound investors, while the outliers either see it as overpriced or inherently risky.
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 100
Attractive to a Defensive Graham Investor
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟢 87
Deep statistical discount — a real Enterprising Investor candidate
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 85
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 80
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 80
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 76
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟢 76
A real, disciplined setup with favorable reward/risk
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 63
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 58
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 53
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 46
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 35
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 31
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 28
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 12
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Based on the last 288 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (2 bullish · 7 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Low confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
-5618.8%
Net Margin
-5026.0%
EBITDA Margin
—
ROE
-42.2%
ROA
-40.6%
ROIC
—
EPS
-$2.66
Cash
$101.58M
Total Debt
—
Current Ratio
26.15
Debt/Equity
0.00
How is Fair Value calculated? →
Current Price
$5.27
Estimated Fair Value (DCF)
-$46.23
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-977.2%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
10.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 10.0% | $-146.79M | $-134.67M |
| 2 | 8.1% | $-158.71M | $-133.59M |
| 3 | 6.3% | $-168.63M | $-130.22M |
| 4 | 4.4% | $-176.01M | $-124.69M |
| 5 | 2.5% | $-180.41M | $-117.25M |
Base FCF (last actual year)
$-133.44M
Terminal Value
$-2.84B
Present Value of Terminal Value
$-1.85B
Enterprise Value
$-2.49B
Net Debt
$0
Equity Value
$-2.49B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$6.26
Tangible Book Value per Share (Tangible NAV)
—
Sentiment based on basic keywords (not AI) — 9 positive, 9 neutral, 2 negative out of the last 20 articles.
MT Newswires · 8.9.2026
Yahoo · 8.9.2026
GlobeNewswire · 8.9.2026
Benzinga · 2.9.2026
Yahoo · 1.9.2026
MT Newswires · 1.9.2026
Yahoo · 1.9.2026
GlobeNewswire · 1.9.2026
Benzinga · 14.8.2026
Benzinga · 12.8.2026
Zacks · 11.8.2026
Yahoo · 11.8.2026
GlobeNewswire · 11.8.2026
Yahoo · 11.8.2026
Benzinga · 11.8.2026
Zacks · 14.7.2026
Insider Monkey · 25.6.2026
Insider Monkey · 23.6.2026
GlobeNewswire · 14.6.2026
MT Newswires · 12.6.2026
Upstream Bio, Inc. (UPB) currently has a StockIQ AI score of 45/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
UPB currently scores 45/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, UPB's estimated fair value is -$46.23, which is 977.2% below the current price of $5.27. This is one valuation model among several signals in the fair-value category, not a price target.
UPB's technical score is 33/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Revenue growth (last year): 20.4%; Earnings per share (EPS) growth: 52.3%; Debt/equity: 0.00.
Based on the real signals StockIQ computed: Estimated fair value: -$46.23 vs. price $5.27 (-977.2%); Operating margin: -5618.8% (negative); Net margin: -5026.0% (negative).
StockIQ has no recorded dividend payment history for UPB.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 13 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Deykin Aaron | Open Market Sale | 16.9.2026 | 32,302 | -895 | $5.49 |
| Houghton Adam | Open Market Sale | 16.9.2026 | 22,901 | -700 | $5.49 |
| Ambrose Allison | Open Market Sale | 16.9.2026 | 15,563 | -485 | $5.49 |
| Sutherland Everett Rand | Open Market Sale | 16.9.2026 | 68,717 | -2,095 | $5.49 |
| GRAY MICHAEL | Open Market Sale | 16.9.2026 | 27,942 | -853 | $5.49 |
| GRAY MICHAEL | Open Market Sale | 16.6.2026 | 853 | -853 | $6.10 |
| Sutherland Everett Rand | Open Market Sale | 16.6.2026 | 2,095 | -2,095 | $6.10 |
| Deykin Aaron | Open Market Sale | 16.6.2026 | 895 | -895 | $6.10 |
| Houghton Adam | Open Market Sale | 16.6.2026 | 700 | -700 | $6.10 |
| Ambrose Allison | Open Market Sale | 16.6.2026 | 477 | -477 | $6.10 |
| GRAY MICHAEL | Open Market Sale | 16.6.2026 | 28,795 | -853 | $6.10 |
| Ruddy Marcella K. | Grant/Award from Employer | 9.6.2026 | 17,096 | +17,096 | — |
| Beckman Daniella | Grant/Award from Employer | 9.6.2026 | 17,096 | +17,096 | — |
| Renaud Ronald C JR | Grant/Award from Employer | 9.6.2026 | 17,096 | +17,096 | — |
| Fleming Harold Edward | Grant/Award from Employer | 9.6.2026 | 17,096 | +17,096 | — |
| Ratcliffe Liam | Grant/Award from Employer | 9.6.2026 | 17,096 | +17,096 | — |
| Chimovits Erez | Grant/Award from Employer | 9.6.2026 | 17,096 | +17,096 | — |
| Renaud Ronald C JR | Grant/Award from Employer | 9.6.2026 | 17,096 | +17,096 | — |
| Beckman Daniella | Grant/Award from Employer | 9.6.2026 | 17,096 | +17,096 | — |
| Ratcliffe Liam | Grant/Award from Employer | 9.6.2026 | 17,096 | +17,096 | — |
| Chimovits Erez | Grant/Award from Employer | 9.6.2026 | 17,096 | +17,096 | — |
| Fleming Harold Edward | Grant/Award from Employer | 9.6.2026 | 17,096 | +17,096 | — |
| Ruddy Marcella K. | Grant/Award from Employer | 9.6.2026 | 17,096 | +17,096 | — |
| GRAY MICHAEL | Open Market Sale | 16.3.2026 | 852 | -852 | $9.29 |
| Ambrose Allison | Open Market Sale | 16.3.2026 | 475 | -475 | $9.29 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
4,490,724 shares short as of 2026-09-15 · vs. 4,095,011 on 2026-08-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
37.6% of trading volume this week was short selling, vs. 45.8% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology